Sanofi Return on Tangible Equity 2010-2023 | SNY

Current and historical return on tangible equity values for Sanofi (SNY) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Sanofi Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
2023-12-31 $5.84B $0.68B -8230.99%
2023-09-30 $9.68B 1359.27%
2023-06-30 $9.02B $-0.97B 1266.99%
2023-03-31 $8.71B 1389.62%
2022-12-31 $8.82B $3.81B 1407.82%
2022-09-30 $8.33B -2546.79%
2022-06-30 $8.13B $-1.31B -2484.71%
2022-03-31 $9.16B inf%
2021-09-30 $8.76B inf%
2021-03-31 $7.99B inf%
2020-09-30 $7.39B inf%
2020-03-31 $6.36B inf%
2019-09-30 $4.98B 358.59%
2019-03-31 $4.86B 349.80%
2018-03-31 $4.71B 213.20%
2017-12-31 $9.53B $5.55B 431.84%
2017-09-30 $9.90B 375.74%
2017-06-30 $9.92B $3.28B 376.72%
2017-03-31 $10.09B 348.25%
2016-12-31 $5.21B $7.26B 179.89%
2016-09-30 $6.19B 571.45%
2016-06-30 $5.76B $4.33B 370.05%
2016-03-31 $5.52B 1092.28%
2015-09-30 $4.90B 1126.39%
2015-06-30 $4.59B $1.89B -380.60%
2014-06-30 $5.57B $0.13B -331.30%
2013-06-30 $6.39B $-0.28B -179.04%
2012-06-30 $8.61B $-6.56B -246.22%
2012-03-31 $8.56B -188.25%
2011-12-31 $9.33B $-7.42B -205.26%
2011-09-30 $8.04B 3127.63%
2011-06-30 $7.45B $-10.76B 2900.39%
2011-03-31 $8.22B 180.72%
2010-12-31 $8.24B $11.79B 181.09%
2010-09-30 $9.30B 279.03%
2010-06-30 $10.37B $6.41B 311.16%
2010-03-31 $11.38B 634.37%
2009-12-31 $10.99B $6.93B 612.79%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $117.002B $46.611B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $834.884B 120.67
Novo Nordisk (NVO) Denmark $639.473B 49.14
Johnson & Johnson (JNJ) United States $350.268B 13.91
Merck (MRK) United States $327.948B 59.67
AbbVie (ABBV) United States $297.708B 15.38
AstraZeneca (AZN) United Kingdom $246.766B 21.45
Novartis AG (NVS) Switzerland $216.092B 15.32
Pfizer (PFE) United States $156.001B 19.39
Innoviva (INVA) United States $0.994B 6.98